Engineered immune-cell therapy research: a readable summary of laboratory and animal studies probing molecular barriers and experimental strategies to enhance anti-tumor durability.
Key Takeaways
- Integrated in vivo and in vitro screens identified NFIL3 as a driver of T-cell dysfunction
- Genetic disruption of NFIL3 prevented engineered T-cell exhaustion and sustained function
- NFIL3-deficient T cells controlled tumors more effectively in animal models